CS Paper Radar

Few-Shot Bioactivity Prediction with Meta-Learning under Assay Heterogeneity

Michal Kmicikiewicz, Tommy Rochussen, Vincent Fortuin, Ewa Szczurek

cs.LG ·submitted 2026-10-05 11:01 UTC · v1

Abstract

Accurate bioactivity prediction is a central challenge in early-stage drug discovery, as individual assays often contain too few measurements to train reliable models independently. Meta-learning offers a principled approach to this few-shot setting, but assay heterogeneity may limit its effectiveness. Here, we test this hypothesis and show that meta-learning performance degrades as meta-training tasks become more heterogeneous. To address this, we introduce MetaHeta, a meta-learning framework that accounts for assay heterogeneity by conditioning predictions on auxiliary data from related assays, with relatedness defined flexibly from available assay information. The architecture of MetaHeta combines linear attention over large auxiliary datasets with exact attention over scarce task-specific context, enabling efficient scaling to the former without compromising exact attention over the latter. We demonstrate the benefits of our approach on assays from ChEMBL and BindingDB, improving few-shot bioactivity prediction and downstream compound prioritization in retrospective Bayesian optimization.

Closest papers

Nearest neighbours by meaning across the whole index.

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

cs.LG ·2026-08-12 ·Antoine de Mathelin, Christopher Tosh, Wesley Tansey
code/data similarity 0.70
Abstract

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.

0.24

Molecular Prior Networks

cs.LG cs.AIcs.CE ·2026-11-03 ·Pawel Gomoluch, Anthony Bradley
publishedbenchmark similarity 0.68
Abstract · Accepted to the NeurIPS 2026 Workshop on AI for Drug Discovery: Bridging the Translation Gap

Predicting affinity between small molecules and their protein targets remains one of the central problems in drug discovery. Due to the substantial cost of wet-lab experiments, machine learning models of drug-target affinity are usually trained on relatively small datasets, ranging from tens to hundreds of molecules. Given the inherent difficulty of generalization between different targets and chemical series, existing datasets of protein-ligand affinities are typically not used for new projects. At the same time, tabular foundation models, including Prior-data Fitted Networks, have recently shown how transformers can be used to solve machine learning problems in a single forward pass of the network, after being trained over a large corpus of, typically, synthetic datasets. Inspired by that line of work, we propose a novel affinity modelling approach, in which the labels of the query molecules are predicted from the labelled support molecules in a single forward pass of a transformer model. The model is trained on thousands of existing affinity datasets, enabling it to capture the general patterns of molecular activity across different targets, chemical series and dataset sizes. For the smallest support sets, our model matches the state of the art on the regression variant of the FS-Mol benchmark, while being faster than existing methods, thanks to the lack of task-specific training. A comparison against a reduced variant of our architecture, which amounts to kernel regression in a meta-learned feature space, shows that the predictive performance of the transformer model is only partially explained by simple molecular similarity.

0.25

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

cs.LG q-bio.QM ·2026-08-11 ·Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens
benchmarkdataset similarity 0.68
Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

0.04

Data-Scarce, Multi-Granular, Multimodal: Benchmark Design for Biosynthetic Gene Clusters

cs.AI ·2026-11-01 ·Hanlin Xiao, Eriko Takano, Mauricio A. Álvarez, Rainer Breitling
top venuebenchmark similarity 0.67
Abstract · 43 pages, including references and appendices. Accepted at NeurIPS 2026 (Evaluations and Datasets Track)

Biosynthetic gene clusters (BGCs) are co-located genes that encode the biosynthesis of specialized metabolites, an important source of antibiotics, anticancer agents, immunosuppressants, and agricultural bioactives. Deep learning, particularly self-supervised foundation models, has spurred interest in BGC sequence modeling, but evaluation has lagged behind: existing benchmarks often rely on coarse classification over small curated datasets, providing limited discrimination among models and insight into downstream utility. We propose a benchmark-design framework in which an informative benchmark should be discriminative, separating models with statistical confidence, and applicable, spanning scientifically meaningful tasks under different levels of generalization. We instantiate this framework as BGC-Bench, which derives five tasks from MIBiG, ranging from A-domain substrate prediction to BGC-molecule retrieval, evaluates them under genotype- and phenotype-shift splits, includes an active-learning setting for label-scarce discovery, and is easily extensible to new tasks and encoders. BGCs further provide a shared testbed across granularities and modalities: BGC-Bench compares twelve encoders on nucleotide, amino-acid, or Pfam-domain sequences, including compositional baselines for each input type, and combines BGC and chemical encoders for cross-modal retrieval. No single representation dominates: the best granularity depends on the biological scale of the task, and pretrained encoders do not consistently outperform other representations across tasks and splits. Active-learning experiments show that most tasks remain data-limited, encoder rankings change with labeling budget, and acquisition strategies yield modest gains. These results show that BGC model evaluation requires task-diverse, shift-aware benchmarks, and the framework can be generalized to benchmark design beyond BGCs.

0.30

D2ML: Models for Direct-to-Biology Small Molecule Screening

cs.LG q-bio.BM ·2026-10-29 ·AkshatKumar Nigam, Neri Amara, Hillary Dequina, Dyana Kenanova, Seth Malmersjo +5 more
published similarity 0.66
Abstract · NeurIPS 2026 Workshop on AI for Drug Discovery (AI4DD)

Direct-to-biology (D2B) screening enables rapid testing of newly synthesized molecules without purification. However, uncertain concentrations in crude mixtures and limited purified-compound measurements complicate the use of these data in machine learning. Here we show that models tailored to the structure of D2B data can improve prediction and guide the discovery of more potent and selective compounds. Our assay-aware models predict activity from single-point screens, relative potency across targets from crude dose-response assays, and absolute potency from purified-compound measurements. For crude assays, potency ratios between targets tested from the same well can retain selectivity information despite uncertain concentrations. A joint model that shares information across stages and balances their contributions to training improved predictions over separate neural networks. The largest gain was in crude dose-response selectivity prediction, where rank correlation increased from 0.27 to 0.40. In a separate experiment, independently trained models guided the selection of 84 new compounds to improve ROS1 potency while limiting activity against the anti-target TRKB. Synthesis and testing identified compounds that extended the measured Pareto front, achieving better combinations of potency and selectivity than those in the training data. The most selective new compound achieved a ROS1 IC50 of 14.7 nM and 233-fold selectivity over TRKB. By comparison, the most selective training compound had a ROS1 IC50 of 20.3 nM and 79-fold selectivity. ATLAS provides the experimental setting for this approach, supporting synthesis and screening of 1,000-10,000 model-selected compounds in two- to three-week cycles. Together, these results show how assay-aware learning can use the full D2B assay sequence to guide multi-objective molecular optimization.

0.16

Beyond Fixed Acquisition Functions: Temporal Difference Active Learning for Perturbation Discovery

cs.LG ·2026-10-15 ·Xudong Zhang, Jianzhe Li, Yitong Tang, Peijie Zhou
similarity 0.65
Abstract · 41 pages, 8 figures (including appendices)

Genetic and drug perturbation screens are important tools for elucidating disease mechanisms and validating therapeutic targets, but experimental costs limit the number of candidates that can be tested. Existing perturbation screening methods typically update the surrogate model with feedback while keeping the acquisition function fixed, limiting their ability to adapt selection to different response landscapes. Experimental feedback reveals current hits and informs subsequent selection by updating candidate predictions, providing a training signal for learning how to select experiments. We formulate budgeted perturbation discovery as a sequential decision problem and propose Temporal Difference Active Learning (TDAL), which learns an acquisition function online through temporal difference learning from a single screening trajectory, accounting for current hits and future discoveries. TDAL uses the Hellinger distance between hit probabilities for unmeasured candidates before and after an experiment to weight successor value, and reuses measured outcomes through leave-batch-out (LBO) to construct virtual transitions and alleviate training data scarcity. Across eight public screens spanning single, double, and triple perturbations under varied experimental configurations, TDAL achieves an average rank of 1.63 among eleven methods and ranks first on four tasks, demonstrating its adaptability across response landscapes.

0.27

ReMedI: Inference-Time Refinement and Self-Distillation for Controllable Molecular Optimization

cs.LG cs.AI ·2026-10-23 ·Jia Yi Zhang, Shivanshu Shekhar, Allison McLevige, Tong Zhang
position similarity 0.65
Abstract

In drug development, lead optimization must improve competing properties, such as increasing permeability and reducing toxicity, while limiting scaffold changes that could compromise the lead's potency. RL-based post-training, such as C-MORAL, addresses this problem by fine-tuning molecular language models to directly optimize molecular leads for objectives of interest, which relies on expensive task-specific datasets and faces challenges in achieving multi-objective optimization (MOO). We argue a pre-trained model may already contain useful molecular edits that zero-shot generation cannot efficiently reach. Motivated by the limited search capabilities of zero-shot generation, we develop an efficient Metropolis-Hastings search strategy to better explore the proposal distribution. We propose ReMedI, which uses the molecular language model as a base proposer for inference-time alignment. Given a lead and a set of multi-objective tasks, the model proposes edits conditioned on the current molecule, while Metropolis--Hastings refinement guides sequential edits under an objective for property improvement, preservation, and lead similarity. On both C-MuMOInstruct and SMDD benchmarks, refinement improves frozen base models across three backbones, reaching significantly higher multi-objective optimization success rates compared to baselines. These search traces can then distilled into the base model which improves zero-shot generation and subsequent search using approximately 7.8 times less training molecular leads than that of C-MORAL. ReMedI achieves approximately 2.8 times the strict-success coverage of RL baseline C-MORAL, including on out-of-distribution tasks, with matched lead-relative similarity.

0.05

PairIT: Autoregressive Transformers for Low-Data Molecule Optimization

cs.LG cs.AIphysics.chem-ph ·2026-10-13 ·Hannah Lawrence, Bodhi P. Vani, Ji Won Park, Natasa Tagasovska, Samuel Don Stanton +3 more
similarity 0.64
Abstract

Generating novel molecules with desired properties is a central challenge in drug discovery. Although foundational work focused on de novo generation, practical use cases require a more complex setting: conditioning on an initial seed molecule, optimizing multiple properties, and operating in data-sparse regimes. We introduce PairIT, a flexible training framework for autoregressive transformers over SMILES sequences that enables seeded generation by learning from pairs of structurally similar molecules. By leveraging matched pairs, the model learns to generate local, chemically meaningful edits that improve a property of the seed molecule. Prompt tokens extend this framework by specifying the target property, desired direction, and approximate magnitude of change. Multiple prompt tokens can be concatenated to enable multi-property optimization at inference time. For properties where pair supervision alone is insufficient, reinforcement learning post-training can further improve optimization, providing a tunable trade-off between proximity to the seed and the optimization objective. PairIT naturally supports pretraining on a large dataset and fine-tuning on a smaller dataset, which is critical for performance in data-sparse regimes. Surprisingly, we observe diminishing returns to the scale of the pretraining dataset. We demonstrate empirically on MoleculeNet and Therapeutics Data Commons datasets that, with appropriate paired-data curation, a standard transformer model of modest size (68M parameters) can achieve robust seeded molecular optimization in low-data regimes.

0.21